NDAINJECTIONINJECTABLEPriority Review
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
3/8 — Basic
Priority Review
INTEGRILIN (eptifibatide) by Merck & Co. is fibrinogen, von willebrand factor, and other adhesive ligands to gp iib/iiia. First approved in 1998.
Drug data last refreshed 12h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTEGRILIN (eptifibatide) is a small-molecule GP IIb/IIIa inhibitor that reversibly blocks platelet aggregation by preventing fibrinogen and von Willebrand factor binding. It is administered intravenously to reduce thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) or those with acute coronary syndromes.
LOE Approaching
As lifecycle approaches loss of exclusivity, commercial teams are typically right-sizing and transitioning focus to pipeline assets or adjacent indications.
Mechanism of Action
fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
Started Feb 2014
70 enrolled
Acute Coronary Syndrome
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Started Apr 2012
535 enrolled
Myocardial InfarctionAcute Coronary SyndromesUnstable Angina
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Started Apr 2010
13,220 enrolled
Acute Coronary Syndrome
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Started Oct 2006
429 enrolled
Infarction, Myocardial
Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome
Started Jun 2006
3,241 enrolled
Coronary Disease
Worked on INTEGRILIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.